PLEASE REVIEW OUR PRIVACY & COOKIES NOTICE

We use cookies to collect and analyze information on site performance and usage and to ensure you can successfully navigate throughout the site. By clicking the “ACCEPT” button to your right or by clicking on any site content, you agree to the placement of cookies on your computer. For more information, see our Privacy Policy.

 
Locations
 
WEBSITES
  • United States (English)
  • International (English)
  • Chinese (中文)
  • French (Français)
  • German (Deutsch)
  • Italian (Italiano)
  • Japanese (日本語)
  • Russian (Русский)
 

Leaving U.S. website

You are now leaving the Haemonetics U.S. website, click 'Yes' to continue or 'No' to stay on the U.S. website.

YesNo
  • Investor Relations
  • LOGIN
    • Haemonetics
    • HSS Client Login
    • Software Download Center
  • REGISTER
  • Home
  • Products
     
    U.S. ProductsView International Products
    Devices
    Blood Center Devices
    • ACP 215
    • MCS+ 8150
    • MCS+ 9000
    • NexSys PCS
    • PCS 2
    Plasma Center Devices
    • NexSys PCS with Persona Technology
    • NexSys PCS with YES Technology
    • NexSys PCS
    • PCS 2
    Surgical and Diagnostic Devices
    • Cell Saver Elite+
    • Cell Saver 5+
    • Cell Saver Elite
    • TEG
    Software
    Hospital Software
    • BloodTrack
    • SafeTrace Tx
    Plasma Center Software
    • DMS
    • NexLynk DMS
    • NextGen
    Services
    Consulting Services
    • Process Improvement
     
  • Solutions
     
    Blood Management Solutions
    • Solutions for Blood Centers
    • Solutions for Hospitals
    • Solutions for Plasma Centers
     
  • Learning Center
     
    Product Training
    • All Products
    • Blood Centers
    • Hospitals
    • Plasma Centers
    Thought Leadership
    • White Papers & Clinical Reviews
    • Reference Lists
    • Poster Abstracts
    Education
       
    • About Haemonetics
       
      Company Background
      • Overview
      • Historical Timeline
      • Leadership Team
      • Scientific Advisory Council

      • Office Locations
      Investor Relations
      • Investor Relations Home
      • Stock Information
      • Earnings
      • Forecasts & Guidance
      Corporate Responsibility
      • Corporate Responsibility at Haemonetics
      Donors Make It Matter
      • Donors Make It Matter Campaign
      News & Events
      • In the News
      • Calendar of Events
      • Publications
      Careers
      • Careers Overview
      • Open Positions
      • Our Global HQ

      Grants

      • Grant Program

       
    • Customer Support

    Leaving U.S. website

    You are now leaving the Haemonetics U.S. website, click 'Yes' to continue or 'No' to stay on the U.S. website.

    YesNo
    • Home
    • Learning Center
    • Thought Leadership
    • Poster Abstracts
    • Contact Us
    • Print
    • Share

    Poster Abstracts

    • AABB 2016

      Orlando, Florida

      • A novel approach for fat removal while maintaining blood quality in a discontinuous autotransfusion device - concept and evaluation
        Conclusions: Based on observations using a transparent centrifugation system, a hypothesis is presented to explain the accumulation of fat in the centrifuge bowl, both in spinning and stopped configurations. Modifications in process parameters and sequence resulted in the development of a dedicated fat removal program. This novel program significantly improves fat removal by the Latham bowl based autotransfusion device CS Elite, thus yielding results equivalent to the continuous autotransfusion system (CATS).
    • AABB 2012

      Boston, Massachusetts

      • Age of Blood Transfused In the United States: Data for 166,208 Transfusions
        Conclusions: For the hospitals studied, the current RBC supply chain and inventory management systems result in 47% of RBC units being transfused more than 3 weeks and 25% more than 4 weeks after their donation. Modifying the current supply chain to provide “fresher” blood will require substantial practice change and system redesign.
      • Blood Transfusion and Length of Stay: How Are They Related?
        Results: LOS was related to Nadir Hgb irrespective of transfusion status. Within each group of Nadir Hgb (except <7 g/dL), patients who received allogeneic blood had longer LOS than those who did not. Patients who received PAD (n=1179) had both longer LOS (3.50 vs. 3.07 days) and higher allogeneic transfusion rates (27.1% vs.17.3%) than those who did not receive PAD.
      • Variability in Transfusion Practice – Beyond Cardiac Surgery
        Methods: We queried a proprietary blood management business intelligence portal (IMPACT® Online, Haemonetics, Braintree, MA) and identified 9 noncardiac procedures associated with substantial red cell (RBC) transfusions. For each procedure, we determined the mean RBC transfusion and utilization rate for the entire hospital stay as well as the standard deviation (SD) of those rates among the participating hospitals (those that contributed at least 20 patients to each data set).
    • SABM 2012

      Pittsburgh, Pennsylvania

      • Periodic data review assures sustainability of blood management programs
        Results: Dramatic reductions in the use of PAD were achieved in each hospital. These improvements were not only sustained but continued during follow up. Similar success and sustainability was seen in the cardiac surgical interventions as reflected in decreased RBC utilization (units/patient including untransfused patients) for patients having coronary artery surgery (CABG).
      • Two unit dosing leads to excess transfusion
        Methods: Using a blood management business intelligence portal (IMPACT® Online, Haemonetics®, Braintree, MA) we determined the hematocrit at discharge of transfused patients who had either unilateral total hip or knee replacements during 2010 or 2011. From a group of 20,758 patients at 15 US hospitals, we removed 105 with incomplete data, 545 without a hematocrit following their last transfusion and 1,194 who received preoperatively donated autologous blood. Of the remaining 18,914, 3,033(16%) received allogeneic RBC.
    • Poster Archives

      Click here to view posters from previous years.
    • Contact Us
    • Terms of Use
    • Quality
    • Careers
    • Privacy Policy
    • Site Map

    © 2011-2020 Haemonetics Corporation